Sign inCreate account

Report workspace tools

NCT00397423COMPLETEDanonymous

Granulocyte-Colony Stimulating Factor Treatment for Amyotrophic Lateral Sclerosis: A Randomized Control Trial Study Assessing Clinical Response

Sponsor

Source record

Peking University

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Granulocyte Colony Stimulating Factor, NS

Indication / condition

AI-normalized

Amyotrophic Lateral Sclerosis

Intervention

Source record

Granulocyte Colony Stimulating Factor, NS

Source & freshness

Source record

NCT ID

NCT00397423

Original source

ClinicalTrials.gov

Source last updated

Nov 28, 2007

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00397423

Title

Granulocyte-Colony Stimulating Factor Treatment for Amyotrophic Lateral Sclerosis: A Randomized Control Trial Study Assessing Clinical Response

Sponsor

Peking University

Status

COMPLETED

Phase

PHASE2

Condition raw

Amyotrophic Lateral Sclerosis

Condition normalized

Amyotrophic Lateral Sclerosis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Granulocyte Colony Stimulating Factor, NS

Target normalized

Granulocyte Colony Stimulating Factor, NS

Interventions

Granulocyte Colony Stimulating Factor, NS

Public preview

Source record

Granulocyte-Colony Stimulating Factor Treatment for Amyotrophic Lateral Sclerosis: A Randomized Control Trial Study Assessing Clinical Response is a PHASE2 clinical asset sponsored by Peking University in Amyotrophic Lateral Sclerosis. SEO and diligence focus: Granulocyte Colony Stimulating Factor, NS, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Granulocyte-Colony Stimulating Factor Treatment for Amyotrophic Lateral Sclerosis: A Randomized Control Trial Study Assessing Clinical Response

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00397423

Status

COMPLETED

Phase

PHASE2

Sponsor

Peking University

Executive brief

Investment-Ready Snapshot

Granulocyte-Colony Stimulating Factor Treatment for Amyotrophic Lateral Sclerosis: A Randomized Control Trial Study Assessing Clinical Response is a PHASE2 clinical asset sponsored by Peking University in Amyotrophic Lateral Sclerosis. SEO and diligence focus: Granulocyte Colony Stimulating Factor, NS, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 28, 2007
Internal syncJun 09, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00397423

Indication

Amyotrophic Lateral Sclerosis

Modality

small molecule

Target

Granulocyte Colony Stimulating Factor, NS

Intervention

Granulocyte Colony Stimulating Factor, NS

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.